Other
Neoplasm by Morphology
CI-CAN-00000002Explore in graph →
Non-malignant13,319 active trials222 approved drugs2,774 evidence items
- NCIt
- C4741
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000002Explore in graph →
Clinical trials
52,657 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07036185 | A Clinical Trail of KJ015 in Patients With HER2-Expressing Solid Tumors | not yet recruiting | Phase 1 | 66 | Shanghai Bao Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jun 25, 2025 | clinicaltrials |
| NCT07034118 | Definitive Proton Radiotherapy Combined With Chemotherapy and Immunotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Phase I Clinical Study | not yet recruiting | Phase 1 | 23 | Anhui Provincial HospitalOTHER_GOV | 1 | Jun 24, 2025 |
| clinicaltrials |
| NCT07032324 | A Clinical Study Exploring CT1190B in the Treatment of Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma ( CT1190B-CG1101 )(CT1190B) | not yet recruiting | Phase 1 | 27 | Qian WenbinOTHER | 1 | Jun 23, 2025 | clinicaltrials |
| NCT07024147 | JWCAR239 in Patients With B Cell Non-Hodgkin Lymphoma | not yet recruiting | Phase 1 | 20 | Peking University Cancer Hospital & InstituteOTHER | 1 | Jun 17, 2025 | clinicaltrials |
| NCT07024394 | Follow-up Study to Evaluate the Safety and Efficacy of FCN-159 in Pediatric Participants With Neurofibromatosis Type 1 | not yet recruiting | Phase 1 / Phase 2 | 65 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.INDUSTRY | 1 | Jun 17, 2025 | clinicaltrials |
| NCT07020260 | The PACMAN-Hu19 Trial: a Study of the Safety and Feasibility of Locally Produced, CD19-targeted and Human CAR T-cell Therapy in Children and Young Adults With Relapsed or Refractory B-cell Malignancies(PACMAN) | not yet recruiting | Phase 1 / Phase 2 | 18 | Princess Maxima Center for Pediatric OncologyOTHER | 1 | Jun 13, 2025 | clinicaltrials |
| NCT06994572 | Study of CT-01 as Monotherapy and Combination Therapy in Subjects With Intermediate or Advanced Hepatocellular Carcinoma | not yet recruiting | Phase 1 | 141 | Captor Therapeutics S.A.INDUSTRY | 0 | May 29, 2025 | clinicaltrials |
| NCT06990620 | TACE Plus Ivonescimab for Unresectable Non-Metastatic HCC(TACE HCC) | not yet recruiting | Phase 1 | 56 | Fudan UniversityOTHER | 0 | May 25, 2025 | clinicaltrials |
| NCT06966583 | NAD+ Supplement（NMN）With Radioimmunotherapy in Advanced NSCLC(NMN) | not yet recruiting | Phase 1 | 20 | Sichuan UniversityOTHER | 1 | May 12, 2025 | clinicaltrials |
| NCT06963502 | A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid Tumors | not yet recruiting | Phase 1 | 762 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | May 9, 2025 | clinicaltrials |
| NCT06870279 | A Clinical Research of CD70-targeted CAR-NKT Cells (CGC738) Therapy in RCC | not yet recruiting | Phase 1 | 28 | RenJi HospitalOTHER | 0 | Apr 24, 2025 | clinicaltrials |
| NCT06934590 | Evaluate Safety and Tolerability of RX001 in Patients With KRAS Mutant Advanced NSCLC | not yet recruiting | Phase 1 | 18 | GeneCraft Inc.INDUSTRY | 1 | Apr 23, 2025 | clinicaltrials |
| NCT06482307 | Molecular Imaging of DNA Damage Response by [18F]-Olaparib PET([18F]-olaparib) | not yet recruiting | Phase 1 / Phase 2 | 10 | University Medical Center GroningenOTHER | 1 | Apr 18, 2025 | clinicaltrials |
| NCT05275374 | XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation(ENHANCE) | not yet recruiting | Phase 1 / Phase 2 | 221 | Xynomic Pharmaceuticals, Inc.INDUSTRY | 0 | Apr 10, 2025 | clinicaltrials |
| NCT06913179 | CAR-T Cell Therapy Combined With Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed or Refractory Multiple Myeloma(CAR-T-allo) | not yet recruiting | Phase 1 | 30 | Xuzhou Medical UniversityOTHER | 0 | Apr 6, 2025 | clinicaltrials |
| NCT06913192 | Efficacy of Sequential BCMA CAR-T Cell Therapy Following Autologous Hematopoietic Stem Cell Transplantation in Transplant-eligible Newly Diagnosed Multiple Myeloma(AUTO-CAR-T) | not yet recruiting | Phase 1 | 50 | Xuzhou Medical UniversityOTHER | 0 | Apr 6, 2025 | clinicaltrials |
| NCT06913218 | A Study of mRNA Vaccines AK154 Monotherapy or in Combination With AK104/AK112,and Sequential mFOLFIRINOX in Surgically Resected PDAC | not yet recruiting | Phase 1 | 60 | AkesoINDUSTRY | 1 | Apr 6, 2025 | clinicaltrials |
| NCT06875791 | Safety and Efficacy Trial of TV5M01 for Radiation-Induced Mucositis in Head and Neck Cancer Patients.(TEMOR) | not yet recruiting | Phase 1 / Phase 2 | 40 | Fundacion Clinica Valle del LiliOTHER | 1 | Apr 1, 2025 | clinicaltrials |
| NCT06896396 | Icaritin Soft Capsules+TACE+Immunotherapy+Targeted Therapy Versus TACE+Immunotherapy+Targeted Therapy for Unresectable Hepatocellular Carcinoma | not yet recruiting | Phase 1 / Phase 2 | 60 | Zhiyong HuangOTHER | 1 | Mar 26, 2025 | clinicaltrials |
| NCT06894693 | A Phase I Clinical Trial of RS001 in Patients with Relapsed/Refractory B-Cell Malignancies | not yet recruiting | Phase 1 | 13 | Guangdong Ruishun Biotech Co., LtdINDUSTRY | 0 | Mar 25, 2025 | clinicaltrials |
| NCT05662904 | Genetic Ablation of CD33 in HSC to Broaden the Therapeutic Index of CD33-directed Immunotherapy in Patients with AML(GALAXY33) | not yet recruiting | Phase 1 | 12 | German Cancer Research CenterOTHER | 1 | Mar 14, 2025 | clinicaltrials |
| NCT06871527 | Fruquintinib Combined With PD-1 Inhibitor and FOLFOX as First-Line Treatment For Advanced Gastric Cancer | not yet recruiting | Phase 1 / Phase 2 | 44 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | Mar 12, 2025 | clinicaltrials |
| NCT06866795 | Phase 1 Clinical Study of GT-220F in Subjects With Metastatic Castration Resistant Prostate Cancer (mCRPC) | not yet recruiting | Phase 1 | 42 | Geode Therapeutics Inc.INDUSTRY | 0 | Mar 10, 2025 | clinicaltrials |
| NCT06846424 | SCT-001 CAR T Cells Therapy for Relapsed and Refractory Ovarian Cancer | not yet recruiting | Phase 1 | 24 | Shanghai Gynecologic Oncology GroupOTHER_GOV | 1 | Feb 26, 2025 | clinicaltrials |
| NCT06845241 | Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma | not yet recruiting | Phase 1 / Phase 2 | 68 | Beijing InnoCare Pharma Tech Co., Ltd.INDUSTRY | 1 | Feb 25, 2025 | clinicaltrials |
| NCT06827080 | Study on the Safety, Tolerability, and Preliminary Efficacy of 161Tb-NYM032 in Patients with Metastatic Castration-Resistant Prostate Cancer | not yet recruiting | Phase 1 / Phase 2 | 15 | Zhengguo ChenOTHER | 0 | Feb 14, 2025 | clinicaltrials |
| NCT05821686 | Efficacy of Interleukin-2 in Triple Negative Breast Cancer | not yet recruiting | Phase 1 / Phase 2 | 10 | Nova Scotia Health AuthorityOTHER | 0 | Feb 12, 2025 | clinicaltrials |
| NCT06822985 | QL1706 As Second-line Treatment in Patients with Advanced Hepatocellular Carcinoma(QL1706) | not yet recruiting | Phase 1 | 21 | Wan-Guang ZhangOTHER | 1 | Feb 12, 2025 | clinicaltrials |
| NCT06823245 | Pharmacokinetic Study of HS-10241 Tablets in Subjects with Hepatic Impairment and Normal Hepatic Function | not yet recruiting | Phase 1 | 32 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 0 | Feb 12, 2025 | clinicaltrials |
| NCT06823258 | Pharmacokinetic Study of HS-10365 Capsule in Subjects with Hepatic Impairment and Normal Hepatic Function | not yet recruiting | Phase 1 | 32 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 0 | Feb 12, 2025 | clinicaltrials |
| NCT06799676 | A Phase Ib/II Clinical Study on the Application of Linperlisib Combined with the VRD Regimen in Newly Diagnosed Patients with Multiple Myeloma | not yet recruiting | Phase 1 / Phase 2 | 42 | Fuling ZhouOTHER | 1 | Jan 29, 2025 | clinicaltrials |
| NCT06783153 | Efficacy and Safety of Adjunctive Use of Rifaximin In Preventing Radiotherapy-induced Diarrhea in Cancer Patients | not yet recruiting | Phase 1 / Phase 2 | 80 | Mansoura UniversityOTHER | 1 | Jan 20, 2025 | clinicaltrials |
| NCT06760676 | A Multiple Tumor Species, Open and Multi-center Clinical Study of Alpaloritovorelli Antibodies (QL-1706) Combined with Pulsed Low Dose Rate External Irradiation (PLDR) for Disease Progression After Previous Anti-tumor Therapy | not yet recruiting | Phase 1 | 90 | Anhui Provincial HospitalOTHER_GOV | 0 | Jan 7, 2025 | clinicaltrials |
| NCT06757387 | Chidamide Plus Golidocitinib in Relapsed/Refractory Peripheral T-Cell Lymphoma | not yet recruiting | Phase 1 / Phase 2 | 45 | Peking University Cancer Hospital & InstituteOTHER | 0 | Jan 3, 2025 | clinicaltrials |
| NCT06748872 | EPITOME-1015-I: a Study to Investigate the Safety and Tolerability of MDG1015 in Patients with Epithelial Ovarian Cancer, Gastroesophageal Adenocarcinoma, Round Cell Liposarcoma And/or Synovial Sarcoma(EPITOME-1015-I) | not yet recruiting | Phase 1 | 55 | Medigene AGINDUSTRY | 1 | Dec 27, 2024 | clinicaltrials |
| NCT06746961 | Efficacy and Safety of QL1706 Plus Lenvatinib As 2nd Line Theapy in Patients with Metastatic Esophageal Carcinoma After Disease Progression on ICIs Therapy | not yet recruiting | Phase 1 / Phase 2 | 49 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 0 | Dec 24, 2024 | clinicaltrials |
| NCT06737146 | Study of MT027 in Patients with Recurrent or Progressive High-grade Glioma | not yet recruiting | Phase 1 | 12 | Suzhou Maximum Bio-tech Co., Ltd.INDUSTRY | 1 | Dec 17, 2024 | clinicaltrials |
| NCT06710561 | The Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Injectable SPN01 in Phase I. | not yet recruiting | Phase 1 | 32 | Beijing SonoPhotoNano Medical Technology Co., Ltd.OTHER | 0 | Dec 3, 2024 | clinicaltrials |
| NCT06712173 | Linperlisib Combined With EZH2 Inhibitor in Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL) | not yet recruiting | Phase 1 | 33 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Dec 2, 2024 | clinicaltrials |
| NCT06705725 | Phase I Clinical Study of CBG002 CAR-T Cell in Treatment of Relapsed/refractory Multiple Myeloma | not yet recruiting | Phase 1 | 38 | Carbiogene Therapeutics Co. Ltd.INDUSTRY | 0 | Nov 26, 2024 | clinicaltrials |
| NCT06699576 | ARTEMIS-103: Phase 1b Study of HS-20093 Combinations in Patients with Bone and Soft Tissue Sarcoma. | not yet recruiting | Phase 1 | 448 | Hansoh BioMedical R&D CompanyINDUSTRY | 0 | Nov 21, 2024 | clinicaltrials |
| NCT06690671 | A Single-Arm, Phase Ⅰb Study of Golidocitinib Combined With Anti-PD-1 for the Treatment of Previously Treated NSCLC | not yet recruiting | Phase 1 / Phase 2 | 30 | Shanghai Chest HospitalOTHER | 1 | Nov 15, 2024 | clinicaltrials |
| NCT06684509 | Atorvaststin and Cardiotoxicity in Acute Myloid Leukemia | not yet recruiting | Phase 1 / Phase 2 | 46 | Assiut UniversityOTHER | 1 | Nov 12, 2024 | clinicaltrials |
| NCT06652529 | Phase 1 Dose Escalation and Expansion to Evaluate AROG4-01 in Patients With Advanced Solid Tumors(AROG4-01-01) | not yet recruiting | Phase 1 | 35 | Aromics TherapeuticsINDUSTRY | 0 | Nov 7, 2024 | clinicaltrials |
| NCT06672263 | A Clinical Trial to Evaluate the Safety and Tolerability of TQB3911 Tablets in Patients With BCR::ABL Fusion Gene Positive Leukemia | not yet recruiting | Phase 1 | 120 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 4, 2024 | clinicaltrials |
| NCT06655519 | An Exploratory Study of RD140 Injection in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia | not yet recruiting | Phase 1 | 12 | Peking University People's HospitalOTHER | 0 | Oct 23, 2024 | clinicaltrials |
| NCT06647329 | CAR-T Technology for Recurrent/Refractory Malignant Hematological and Lymphatic Tumors(CAR-T Therapy) | not yet recruiting | Phase 1 | 30 | Mingzhi ZhangOTHER | 1 | Oct 17, 2024 | clinicaltrials |
| NCT06641453 | CAR-T Cell Therapy Targeting GPC3 in Patients with Advanced GPC3-Positive Hepatocellular Carcinoma | not yet recruiting | Phase 1 / Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | Oct 16, 2024 | clinicaltrials |
| NCT06597513 | Auto-HSCT-Supported Dose-Dense Chemotherapy with Adebrelimab As First-Line Treatment for ES-SCLC | not yet recruiting | Phase 1 / Phase 2 | 10 | Zhou ChengzhiOTHER | 0 | Oct 15, 2024 | clinicaltrials |
| NCT06641024 | Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/ Refractory B-ALL | not yet recruiting | Phase 1 | 24 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Oct 15, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Jun 25, 2025source: clinicaltrials